News

  • Nov 2020
    COMING SOON: "Kairos" Particle Sorter

    A bio-hazard safe particle sorting system based on a completely new particle sorting technology. Electric field driven (fast and specific) particle sorting technology plucks particles from the flow cytometer's sample stream with far greater speed and precision than is possible by piezoelectric methods.

    Contact us for more information.

  • Jun 2020
    Launch of Apogee Flow Asia Ltd.

    A new company has been formed to serve ApogeeFlow's growing customer base in the Asia-Pacific region.

    Conveniently located in the heart of Hong Kong's renowned commercial district, Apogee Flow Asia Ltd. employs staff with many years of experience supporting ApogeeFlow cytometers. The launch of Apogee Flow Asia Ltd. is an important benchmark in ApogeeFlow's development and will provide facilities for demonstration, training and applications development.

  • Oct 2019
    Nanostics Expands ClarityDX Prostate Clinical Study into the United States

    @Nanostics' ClarityDX Prostate clinical validation study is expanding into the US with the Century Clinical Research, Inc. recruitment site in Daytona Beach, FL. This expansion will significantly accelerate the clinical study timeline while increasing patient cohort diversity.

    Nanostics have selected ApogeeFlow's platform for this program.

    Key points:

    • Nanostics is expanding its ClarityDX Prostate clinical validation study into the US by opening the Florid...
  • Jul 2019
    Apogee at ISEV / MRS Joint Extracellular Vesicle Conference

    ApogeeFlow and Nanostics will exhibit at the First ISEV & MRS Joint Extracellular Vesicle Conference focused on cancer.

    Nashville, 2nd-4th August 2019

     

    First ISEV & MRS Joint Extracellular Vesicle Conference

  • Jun 2019
    Press Release: Nanostics Clinical Validation Study

    This clinical study is being conducted with Apogee Microflow technology and in partnership with Apogee Flow Systems.

    Nanostics Announces Launch of its Clinical Validation Study for ClarityDX Prostate

    Nanostics Inc., a company developing a novel liquid biopsy platform for the early diagnosis of clinically significant prostate cancer, is pleased to announce the start of its key clinical validation study. The study will be carried out with blood to be sampled from 2,800 men with ele...

< | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | Next | >
Get In Touch
Follow:
Visit our Facebook page Follow us on Twitter Connect with us on LinkedIn
Share: